BioBuzz has partnered with Wilson Sonsini Goodrich & Rosati for the second installment of the #CEOTalks event series. This event will bring you insights from local company executives on the game changing technologies they are bringing to market to address one of the greatest public health threats of our age; multi-drug resistant bacteria and other infectious agents. However, bringing new treatments to market in this field is made harder by a unique set of market condition and investment hurddles that executives need to navigate to be successful.

Join us to hear from an all-star panel of executives who will discuss the opportunities and challenges they face as their companies bring new therapies to the bedside. These CEOs are making their mark in the field, each with a different approach, and at different stages of commercialization and funding. We will dive deep with these three cutting-edge and diverse technologies to show how they are combating drug resistance to save lives. 

Panelists:

• Carol Nacy, Ph.D., CEO, Sequella
• Greg Merril,  CEO, Adaptive Phage Therapeutics
• Mena Izadjoo, Ph.D., President & CSO, Integrated Pharma Services
• Moderator - Charles Andres, Phd, RAC - Associate at Wilson Sonsini Goodrich & Rosati

Agenda:

4:30 pm - Arrival & Networking
5:00 pm - Discussion and Q&A
6:30 - 7:30 pm - Networking & refreshments

Guests are invited to stay after the discussion to enjoy refreshments and continue the conversation with our panelists and other guests in true BioBuzz style.  

Guest Invitations:

Space is limited for this exclusive event. If you are interested in attending, please contact BioBuzz or one of our sponsors to recieve an invitation and registration code if you have not received one. 

Please register below with your registration code and we look forward to seeing you at what will be a great evening of discussion and networking in the BioHealth Capital Region.

Meet our Panelists:

Carol A. Nacy, Ph.D. - Co-Founder and CEO, Sequella Inc.

served as our CEO and Chairman of the Board since 1999. Prior to Sequella, Dr. Nacy served during 1997 and 1998 as Chief Scientific Officer (CSO) for Anergen, Inc. (NASDAQ: ANRG), a California company acquired by Corixa Corporation in December 1998. From 1993 through 1997, Dr. Nacy was Executive Vice President and CSO at EntreMed, Inc. (NASDAQ: ENMD) and participated in its successful initial public offering in June 1996. Previously, Dr. Nacy was Career Scientist (GS-15) at the Walter Reed Army Institute of Research, Washington, DC. Dr. Nacy currently serves on board of directors of companies and non-profit agencies.

 

 

Greg Merril - CEO, Adaptive Phage Therapeutics

Greg Merril an experienced life science entrepreneurial executive. He has served as founding CEO for four VC-backed fast growth health-related product companies. As founding CEO of HT Medical Systems he led the Company through a $42 million merger with Immersion Corp (NASDAQ: IMMR). Greg has delivered over fifty invited lectures and keynote addresses covering business development, virtual reality, and medical technology. He has authored numerous peer reviewed technical papers and has been awarded nineteen patents. Greg championed a Congressional appropriation funding a simulation -based medical training and certification initiative. He served as invited Guest Editor for the Proceedings of the IEEE Special Issue on Virtual and Augmented Reality in Medicine. He has served as Principal Investigator on numerous federally funded research grants and as a referee/reviewer for government-sponsored and non-profit grants related to medical informatics and virtual reality technologies. While leading Brain Sentry, Inc. Greg was recognized as a TEDMED Innovation Scholar for his work developing and commercializing head impact sensor technology.  During his career Greg’s product developed efforts have been recognized twice as Innovation of the Year by the Consumer Electronic Association (CEA)/ Industrial Designers Society of America (IDSA).  Other awards have included the 2015 International Sports Technology Award for Best Wearable Technology, A Wall Street Journal Startup Company of the Year (2013), BusinessWeek Product Design of the Year; Popular Science “Best of What’s New” winner.  Greg’s efforts have been recognized as a regional Ernst & Young Entrepreneur of the Year winner. 

Mena Izadoo, Ph.D. - President & CSO, Integrated Pharma Services

Officer of Integrated Pharma Services (IPS) and Integrated MicroSciences (IMS). Prior to her current position she was the Vice President and Chief Science Officer of Trideum Biosciences. Formerly, she was “Senior Distinguished Scientist” and Director of the Diagnostics and Translational Research Center (DTRC) of the Henry M. Jackson Foundation (HJF) for Advancement of Military Medicine. She served as the Chief of Microbiology and Wound Biology and Translational Research (WBTR) Division at the Armed Forces Institute of Pathology (AFIP) in Washington DC prior to her position at HJF. While at AFIP, she was awarded the title of “Distinguished Scientist” in accordance with the Public Law 94-36 for demonstrated ability and experience to enhance the activities of the AFIP in consultation, education, and research. Dr. Izadjoo holds an Associate Professorship at Uniformed Services University for Health Sciences (USUHS) and is the President of Washington Academy of Sciences. 

Dr. Izadjoo received her PhD in Microbiology from Louisiana State University in 1992. This was followed by six years of post-doctoral fellowships at Texas A&M University and NIH in molecular biology and immunogenomics. Her research efforts have been focused on developing and evaluating diagnostics and therapeutics for bio-warfare agents and drug-resistant pathogens. Her work with Dr. Sidney Altman, a Noble Prize Laurette from Yale University, led to development of novel therapeutics for number of select agents.

Moderator - Charles Andres, Phd, RAC - Associate at Wilson Sonsini Goodrich & Rosati

Charles Andres, Ph.D., RAC, is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati. He focuses on patent prosecution, strategic patent counseling, IP due diligence, drug and medical device FDA regulatory counseling, invalidity and non-infringement opinions, life-cycle management, Supreme Court and Federal Circuit amicus briefs, and related business matters. Prior to becoming a patent professional, Charlie spent a decade as a medicinal chemist and early-phase project co-chair at Bristol-Myers Squibb Company, where he won a Presidential Award, among other accolades. He holds Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professionals Society.

Please contact BioBuzz or a representative from one of our Sponsors for information on attendance.

Annual Sponsors: